Skip to main content
. 2020 Dec 14;124(6):1121–1129. doi: 10.1038/s41416-020-01204-w

Table 4.

Multivariate analysis of prognostic markers in LN-negative patients.

LN-negative patients HR (95% CI) P valueb
Model 1
Minimal TFD (I) 0.9 (0.81; 1.01) 0.079
Tumour type Adeno (ref. squamo) 1.46 (0.46; 4.59) 0.521
Adenosquamo (ref. squamo) 6.87 (1.82; 25.92) 0.004
Model 2
TFD(I) binariseda ≤3.5 (ref. >3.5) 3.57 (1.15; 11.09) 0.028
Tumour type Adeno (ref. squamo) 1.48 (0.47; 4.66) 0.506
Adenosquamo (ref. spino) 6.41 (1.70; 24.22) 0.006
Model 3
TFD (I) binariseda ≤3.5 (ref. >3.5) 3.93 (1.25; 12.39) 0.020
Tumour type Adeno (ref. squamo) 1.47 (0.47; 4.63) 0.511
Adenosquamo (ref. squamo) 5.83 (1.53; 22.24) 0.010
LVSI Yes (ref. no) 0.60 (0.19; 1.88) 0.383
Model 4
TFD (I) binariseda ≤3.5 (ref. >3.5) 2.90 (0.51; 16.34) 0.229
Tumour type Adeno (ref. squamo) 1.46 (0.38; 5.58) 0.580
Adenosquamous (ref. squamo) 2.18 (0.27; 17.95) 0.468
Stromal invasion (P) 1 (0.89; 1.13) 0.959
Model 5
Largest tumour size (P) binariseda >25.5 (ref. ≤25.5) 1.35 (0.58; 3.13) 0.480
Tumour type Adeno (ref. squamo) 2.37 (0.94; 5.95) 0.067
Adenosquamous (ref. squamo) 7.53 (2.05; 27.68) 0.002

adeno adenocarcinoma, CI confidence interval, LN lymph node, LVSI lymphovascular space invasion, squamo squamous cell cancer, TFD tumour-free distance, (I) assessed by imaging, (P) assessed by pathology.

aCut-off determined by ROC analysis, the criterion was the highest value of the sum of sensitivity and specificity; blevel of significance P < 0.05.